Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/karger/osteopontin-and-melanoma-inhibitory-activity-comparison-of-two-x5v2EHM5ym
References (20)
-
P. Stieber, V. Heinemann, A. Schalhorn (2005)
[Tumor markers--how they should be applied].MMW Fortschritte der Medizin, 147 20
-
C. Mooy, P. Jong (1996)
Prognostic parameters in uveal melanoma: a review.Survey of ophthalmology, 41 3
-
R. Folberg, M. Mehaffey, L. Gardner, M. Meyer, V. Rummelt, J. Pe’er (1997)
The microcirculation of choroidal and ciliary body melanomasEye, 11
-
U. Schaller, A. Mueller, A. Bosserhoff, S. Haraida, U. Löhrs, R. Buettner, A. Kampik (2000)
[Melanoma inhibitory activity (MIA). Evaluation of a new tumor-associated antigen as a serum marker for uveal melanomas].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 97 6
-
S. Eskelin, S. Pyrhönen, P. Summanen, J. Prause, T. Kivelä (1999)
Screening for metastatic malignant melanoma of the uvea revisitedCancer, 85
-
L. Brown, A. Papadopoulos-Sergiou, B. Berse, E. Manseau, K. Tognazzi, C. Perruzzi, H. Dvorak, D. Senger (1994)
Osteopontin expression and distribution in human carcinomas.The American journal of pathology, 145 3
-
T. Standal, M. Børset, A. Sundan (2004)
Role of osteopontin in adhesion, migration, cell survival and bone remodeling.Experimental oncology, 26 3
-
C. Metz (1978)
Basic principles of ROC analysis.Seminars in nuclear medicine, 8 4
-
M. Diener-West, S. Reynolds, Donna Agugliaro, R. Caldwell, K. Cumming, J. Earle, Donna Green, B. Hawkins, J. Hayman, I. Jaiyesimi, J. Kirkwood, W. Koh, D. Robertson, J. Shaw, J. Thoma (2004)
Screening for metastasis from choroidal melanoma: the Collaborative Ocular Melanoma Study Group Report 23.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 12
-
V. Barak, S. Frenkel, I. Kalickman, A. Maniotis, R. Folberg, J. Pe’er (2007)
Serum markers to detect metastatic uveal melanoma.Anticancer research, 27 4A
-
I. Reiniger, U. Schaller, C. Haritoglou, R. Hein, A. Bosserhoff, A. Kampik, A. Mueller (2005)
“Melanoma inhibitory activity” (MIA): a promising serological tumour marker in metastatic uveal melanomaGraefe's Archive for Clinical and Experimental Ophthalmology, 243
-
U. Schaller, A. Bosserhoff, A. Neubauer, R. Buettner, A. Kampik, A. Mueller (2002)
Melanoma inhibitory activity: a novel serum marker for uveal melanomaMelanoma Research, 12
-
(2004)
Role of osteopontin in tumor progression -
I. Reiniger, A. Wolf, U. Welge-Lüssen, A. Mueller, A. Kampik, U. Schaller (2007)
Osteopontin as a serologic marker for metastatic uveal melanoma: results of a pilot study.American journal of ophthalmology, 143 4
-
A. Bedikian (2006)
Metastatic Uveal Melanoma Therapy: Current OptionsInternational Ophthalmology Clinics, 46
-
S. Kadkol, A. Lin, V. Barak, I. Kalickman, L. Leach, K. Valyi‐Nagy, D. Majumdar, S. Setty, A. Maniotis, R. Folberg, J. Pe’er (2006)
Osteopontin expression and serum levels in metastatic uveal melanoma: a pilot study.Investigative ophthalmology & visual science, 47 3
-
Ossoinig Kc, F. Bigar, Kaefring Sl (1975)
Malignant melanoma of the choroid and ciliary body. A differential diagnosis in clinical echography.Bibliotheca ophthalmologica : supplementa ad ophthalmologica, 83
-
U. Schaller, A. Mueller, A. Bosserhoff, S. Haraida, U. Löhrs, R. Buettner, A. Kampik (2000)
Melanoma inhibitory activity (MIA) Evaluierung eines neuen tumorassoziierten Antigens als Serummarker für uveale MelanomeDer Ophthalmologe, 97
-
A. Bosserhoff, M. Kaufmann, B. Kaluza, I. Bartke, H. Zirngibl, R. Hein, Wilhelm Stolz, R. Buettner (1997)
Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma.Cancer research, 57 15
-
D. Denhardt (2005)
Osteopontin expression correlates with melanoma invasion.The Journal of investigative dermatology, 124 5
- Publisher
- Karger
- Copyright
- © 2009 S. Karger AG, Basel
- ISSN
- 0030-3755
- eISSN
- 1423-0267
- DOI
- 10.1159/000206139
- Publisher site
- See Article on Publisher Site
Abstract
Background: Evaluation of the protein osteopontin (OPN) as a potential new marker in comparison to melanoma inhibitory activity (MIA) for screening and detection of metastatic uveal melanoma. Methods: Plasma levels of 32 patients with uveal melanoma were analyzed for OPN and MIA by enzyme-linked immunosorbent assay (ELISA). Fourteen of these patients had clinically detectable liver metastases. Results: Median plasma concentration of OPN in patients with metastatic disease was 152.01 ng/ml compared to 47.39 ng/ml in patients without clinically detectable metastases (p < 0.001). The difference between the median MIA plasma levels in patients with (13.11 ng/ml) and patients without (5.64 ng/ml) metastatic disease was also statistically significant (p < 0.001). No correlation could be found between MIA or OPN levels and tumor height in patients without clinically detectable metastases. Conclusion: The proteins MIA and OPN seem to be promising tumor markers for the metastasis screening in patients with uveal melanoma.
Journal
Ophthalmologica – Karger
Published: Jan 1, 2009
Keywords: Serological marker; Uveal melanoma; Metastases; Osteopontin; Melanoma inhibitory activity